Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

100%

6 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

4 recruiting1 with results

Enrollment Performance

Analytics

Phase 4

6(100.0%)

6Total

Phase 4(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04232917Phase 4Recruiting

Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections.

Role: lead

NCT04065971Phase 4Recruiting

Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections.

Role: lead

NCT04308278Phase 4Recruiting

Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection

Role: lead

NCT03977753Phase 4Recruiting

Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts

Role: lead

NCT04235322Phase 4Terminated

Study of 2LHERP® in Genital Herpes Infections

Role: lead

NCT02690935Phase 4Completed

Efficacy of 2LALERG (Homeopathic Drug) in Allergic Rhinitis Related to Grass Pollen

Role: lead

All 6 trials loaded